The control of neuritis in leprosy with clofazimine.
D000293:Adolescent; D000328:Adult; D000349:Africa; D000758:Anesthesia; D000814:Aniline Compounds / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D002991:Clofazimine / Q000008:administration & dosage / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006984:Hypertrophy / Q000188:drug therapy; D007918:Leprosy / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009443:Neuritis / Q000150:complications / Q000517:prevention & control*; D010243:Paralysis / Q000188:drug therapy; D010525:Peripheral Nerves / Q000503:physiopathology; D010647:Phenyl Ethers / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013890:Thiourea / Q000627:therapeutic use
D000814:Aniline Compounds; D010647:Phenyl Ethers; D003622:Dapsone; D002991:Clofazimine; D013890:Thiourea; D011241:Prednisone